Metropolis Q1FY26 revenue up 23% YoY, PAT rises 19% to ₹45 Cr
Metropolis
Healthcare Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2025.
In Q1FY26, patient volumes increased by 11 per cent year-on-year (YoY), while test volumes grew by 12 per cent.
Revenue from the business-to-consumer (B2C) segment rose 19 per cent YoY, and business-to-business (B2B) revenue grew 29 per cent.
The company also reported an 11 per cent increase in revenue per patient (RPP) and a 10 per cent rise in revenue per test (RPT), supported by a richer test mix, scientific upselling, and the adoption of its recommendation engine.
Specialty diagnostics posted the highest revenue growth at 32 per cent, driven by strong demand in oncology, genomics, next-generation sequencing (NGS), and women and child health services.
According to the company, this growth was supported by scientific engagement initiatives, the use of artificial intelligence, and innovation-led differentiation.
The TruHealth wellness and illness bundled portfolio grew 24 per cent YoY, with demand led by premium packages that include home-based ECG, vital checks, and consultations, reflecting increasing interest in preventive and integrated healthcare solutions.
It is stated that geographically, North India's revenue contribution rose to 17 per cent from 8 per cent a year earlier, while Tier III cities recorded revenue growth of 17 per cent.
The company noted that recent acquisitions have been fully integrated from both financial and operational perspectives, in line with its strategic plan.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 days ago
- Time of India
Metropolis Q1FY26 revenue up 23% YoY, PAT rises 19% to ₹45 Cr
Mumbai: Metropolis Healthcare Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2025. In Q1FY26, patient volumes increased by 11 per cent year-on-year (YoY), while test volumes grew by 12 per cent. Revenue from the business-to-consumer (B2C) segment rose 19 per cent YoY, and business-to-business (B2B) revenue grew 29 per cent. The company also reported an 11 per cent increase in revenue per patient (RPP) and a 10 per cent rise in revenue per test (RPT), supported by a richer test mix, scientific upselling, and the adoption of its recommendation engine. Specialty diagnostics posted the highest revenue growth at 32 per cent, driven by strong demand in oncology, genomics, next-generation sequencing (NGS), and women and child health services. According to the company, this growth was supported by scientific engagement initiatives, the use of artificial intelligence, and innovation-led differentiation. The TruHealth wellness and illness bundled portfolio grew 24 per cent YoY, with demand led by premium packages that include home-based ECG, vital checks, and consultations, reflecting increasing interest in preventive and integrated healthcare solutions. It is stated that geographically, North India's revenue contribution rose to 17 per cent from 8 per cent a year earlier, while Tier III cities recorded revenue growth of 17 per cent. The company noted that recent acquisitions have been fully integrated from both financial and operational perspectives, in line with its strategic plan.
News18
18-07-2025
- News18
Cough, Cold, Or Something Worse? Why You Shouldn't Ignore Monsoon Flu Symptoms
Last Updated: Monsoon offers a breeding ground for the spread of viruses and bacteria. What looks like a common cold or viral fever might actually indicate something deeper. As the monsoon clouds roll in and bring a welcome respite from the heat, there's another problem that creeps up alongside – one filled with the heightened risk of infections. While many of us dismiss the flu during the rainy months as just a product of the weather change, this approach can be dangerous. The monsoon season in India is a breeding ground for numerous infections, and flu is one of the most commonly misinterpreted illnesses. What starts as a mild cold or fever is often treated with over-the-counter remedies, including antibiotics, which can actually worsen the problem. The onset of monsoon is accompanied by high humidity and pathogens, all of which create the perfect storm for the spread of viruses and bacteria. People often confuse flu-like symptoms with a common cold or the seasonal bug. This delay in recognising the illness can lead to more severe complications. Dr. Mahua Das Gupta, Director of Medical Affairs (Infectious Diseases) at HaystackAnalytics, says, 'Infections caused by respiratory viruses such as Influenza A (H1N1), H3N2, SARS-CoV2 and RSV can be severe, especially for those with compromised immune systems or pre-existing conditions like asthma, diabetes, and heart disease." The Risk of Misdiagnosis: Self-Treatment and Antibiotic Resistance In the rush to feel better, many people opt for self-medication, often reaching for antibiotics at the first sign of fever or cold. Dr Gupta says, 'This overuse of antibiotics has contributed to a growing problem – antimicrobial resistance (AMR). The WHO identifies AMR as one of the top ten global health threats, with an estimated 5 million deaths annually attributed to drug-resistant infections." 'The overuse of antibiotics accelerates the development of antibiotic-resistant bacteria, making future infections more difficult to treat. More dangerously, the symptoms can escalate into complications like pneumonia or even organ failure, requiring hospitalizations that could have been avoided with earlier, more accurate diagnosis and appropriate treatment," adds Dr Gupta. Early Diagnostics: The Key to Preventing Serious Illnesses The good news is that early diagnostic tools can help prevent the flu from escalating into more severe conditions. Dr Gupta says, 'Advanced technologies, like Next-Generation Sequencing (NGS), enable clinicians to identify pathogens at the genomic level with speed and accuracy that surpass traditional methods. NGS can detect the specific virus or bacteria causing the infection, even those that are difficult to culture or detect, using older diagnostic methods." NGS can detect a wide range of pathogens in a single test, including bacterial, fungal, and viral agents responsible for respiratory infections, and even reveal the antimicrobial resistance profiles of these pathogens. With a turnaround time as quick as 24 hours, this technology empowers clinicians to initiate the most effective treatment without delay. How Genomics Can Help with Flu Diagnosis NGS-based diagnostic tests can help physicians move beyond broad-spectrum antibiotics and make data-driven treatment decisions. These tests provide a clear picture of which pathogens are involved, whether viral, bacterial, or fungal, allowing for targeted treatment. Dr Gupta explains, 'By providing a comprehensive pathogen profile, genomic tests also enable doctors to understand the exact nature of a patient's infection. Instead of relying on trial-and-error, doctors can make informed decisions about whether to prescribe antiviral medications, manage symptoms, or employ more aggressive treatments." A Call for Vigilance: The Role of Preventive Care As the monsoon season approaches, it's crucial to stay vigilant about flu and other infections. Flu-like symptoms during this time shouldn't be dismissed as just the weather. Early intervention with proper diagnostics can prevent complications, reduce unnecessary antibiotic use, and combat antimicrobial resistance. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Indian Express
17-07-2025
- Indian Express
Homi Bhabha centre begins DNA, RNA-based technology for advanced cancer diagnosis
Bringing cutting-edge technology to patient care, the Department of Oncopathology at Homi Bhabha Cancer Hospital and Research Centre, Punjab has initiated DNA and RNA-based Next Generation Sequencing (NGS) for advanced cancer diagnosis and personalised treatment in its New Chandigarh unit in Mohali. NGS is a molecular diagnostic technology that enables rapid and comprehensive analysis of DNA and RNA, which helps to identify genetic mutations that drive cancer. This powerful tool allows doctors to tailor treatment plans based on a patient's unique tumour profile, ensuring more precise and effective therapy. It also plays a crucial role in detecting hereditary cancer syndromes and monitoring disease progression or recurrence. With this addition, the hospital further strengthens its commitment to offering world-class and personalised cancer care. The service is now available for patients with both solid tumours and blood cancers. Dr Ashish Gulia, director of the hospital, stated that very few hospitals in this part of the country offer this testing facility. He highlighted how cancer treatment is becoming increasingly specialised. In the past, there were only a few types of chemotherapy and treatments, and cancer categories were limited. Taking lung cancer as an example, he explained that previously, there were just two types. Now, by checking the genetic profile of lung cancer, doctors can determine its specific type. This test offers two main benefits. Firstly, it helps identify which cancers are treatable and the ones incurable. This allows medical professionals to focus their efforts effectively, rather than applying the same energy to all types of cancer. Second, the test reveals specific tumours that can be treated in a specialised way, leading to better treatment outcomes. Comparing past and present technology, Gulia noted that a decade ago, a lung cancer diagnosis often meant a bleak prognosis. However, with NGS, it is now possible to treat such patients much more effectively. Dr Sankalp Sancheti, head, Department of Oncopathology, Homi Bhabha Cancer Hospital and Research Centre, described the new high-end test as a complex process, and previously, samples for this test had to be sent to Mumbai. Now, with the facility available in-house, it will save considerable time for both the hospital and patients, thereby improving convenience. The cancer hospital is a tertiary care hospital with a 300-bed capacity, built at the cost of over Rs 660 crore by Tata Memorial Centre, an aided institute under the Department of Atomic Energy, Government of India. The hospital functions like a 'hub' of cancer care and treatment in the region, with the 100-bedded hospital in Sangrur functioning as its 'spoke' as part of the hub and spoke model.
